Search research articles
Contact Us
Filters
Showing results (151-160 of 155) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 155 results.
Acta Biomaterialia
|
January 9, 2008
In vitro behaviour of adult mesenchymal stem cells seeded on a bioactive glass ceramic in the SiO(2)-CaO-P(2)O(5) system
L Meseguer-Olmo, A Bernabeu-Esclapez, E Ros-Martinez, et al.
Nature Communications
|
March 19, 2014
Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity
Zenita Adhireksan, Gabriela E Davey, Pablo Campomanes, et al.
Cancer Chemotherapy and Pharmacology
|
March 6, 1998
Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors
B Tranchand, G Catimel, C Lucas, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
March 22, 2003
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]
F Mornex, L Thomas, P Mohr, et al.
Melanoma Research
|
February 6, 2003
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma
F Mornex, L Thomas, P Mohr, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 155) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 155 results.
Acta Biomaterialia
|
January 9, 2008
In vitro behaviour of adult mesenchymal stem cells seeded on a bioactive glass ceramic in the SiO(2)-CaO-P(2)O(5) system
L Meseguer-Olmo, A Bernabeu-Esclapez, E Ros-Martinez, et al.
Nature Communications
|
March 19, 2014
Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity
Zenita Adhireksan, Gabriela E Davey, Pablo Campomanes, et al.
Cancer Chemotherapy and Pharmacology
|
March 6, 1998
Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors
B Tranchand, G Catimel, C Lucas, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
March 22, 2003
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]
F Mornex, L Thomas, P Mohr, et al.
Melanoma Research
|
February 6, 2003
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma
F Mornex, L Thomas, P Mohr, et al.
Page
of 16